Pharmacological management of arrhythmias in the elderly

Drugs and Aging

Volumn 11, Issue 2, 1997, Pages 96-110

  Van Gelder, Isabelle C ^a   Brügemann, Johan ^a   Crijns, Harry J G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; LIDOCAINE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE SULFATE; SOTALOL; VERAPAMIL;

ANKLE EDEMA; ATRIOVENTRICULAR BLOCK; BRONCHOSPASM; CATHETER ABLATION; CONSTIPATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; IMPOTENCE; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SINUS BRADYCARDIA; SPEECH DISORDER; THYROID DISEASE; TORSADE DES POINTES; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0030749907     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711020-00002     Document Type: Review

References (65)

1. Kulbertus HE, de Leval-Rutten F, Bartsch P, et al. Atrial fibrillation in elderly, ambulatory patients. In: Kulbertus HE, Olsson SB, Schlepper M, editors. Atrial fibrillation. Mölndal: AB Hassle, 1981: 148-56
2. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation. N Engl J Med 1982; 306: 1018-22
3. Packer DL, Bardy OH, Worley SJ, et al. Tachycardia-induced cardiomyopathy : a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563-70
4. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24-38A
5. Crijns HJGM, Van Wijk LM, Van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acelate: comparison of two regimens, Eur Heart J 1988; 9: 634-8
6. Suttorp MJ, Kingma HJ, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-7
7. Fresco C, Proclemer A, on behalf of the PAFIT-2 Investigators. Management of recent onset atrial fibrillation. Eur Heart J 1996; 17 Suppl. C:41-7
8. Levine JH, Moganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type IA compared with IC antiarrhythmic drug therapy. Circulation 1989; 80: 1063-9
9. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987; 106: 503-6
10. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the Diltiazem - Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63: 1046-51
11. Stambler BS, Wood MA, Ellenbogen KA, the lbutilide Repeat Dose Study investigators, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-21
12. Hou Z-Y, Chang M-S, Chen C-Y, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized. digoxin-controlled study. Eur Heart J 1995; 16: 521-8
13. Lown B. Electrical cardioversion of cardiac arrhythmias. Br Heart J 1967; 29: 469-87
14. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6
15. Van Gelder IC, Crijns HJGM, Heesen WF, et al. Atrial fibrillation in the elderly: is the same therapeutic strategy feasible [abstract]? J Am Coll Cardiol 1994; 23: 368A
16. Björk U, Karesoja M, Hirvonen P. Elective cardioversion in the elderly, In: Olsson SB, Allessie MA, Campbell RWF. editors. Atrial fibrillation: mechanisms and therapeutic strategies. Armonk (NY): Futura. 1994: 343-8
17. Carlsson J, Tebbe U, Rox J, et al., for the ALKK-Study group. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 1996; 78: 1380-4
18. Van Gelder IC, Crijns HJGM. Tieleman RG, et al. Value and limitation of electrical cardioversion in patients with chronic atrial fibrillation - importance of arrhythmia risk factors and oral anticoagulation. Arch Intern Med 1996; 156: 2585-92
19. Tran HT. Torsades de pointes induced by nonantiarrhythmic drugs. Conn Med 1994; 58: 291-5
20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12
21. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44: 1378-82
22. Lundstrom T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90
23. Robertson CE, Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter. Br Heart J 1980; 44: 602-3
24. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990; 66: 378-83
25. Juul-Möller S, Edvardsson N, Rehnquist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-9
26. Crijns HJGM, Gosselink ATM, Van Gelder IC, et al. Drugs after cardioversion to prevent relapses of chronic atrial fibrillation. In: Kingma JH, van Hemel NM, Lie KI, editors. Atrial fibrillation: a treatable disease? Dordrecht: Kluwer Academic Publishers, 1992: 105-48
27. Epstein LM, Chiesa N, Wong MN, et al. Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly. J Am Coll Cardiol 1994; 23: 1356-62
28. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5
29. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II: echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12
30. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147: 1561-4
31. Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; 1: 175-8
32. Stroke Prevention in Atrial Fibrillation Study Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991; 84: 527-39
33. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11
34. Connolly SJ, Laupacis A, Gent M, et al. for the CAFA Study Coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55
35. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12
36. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-91
37. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention of Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8
38. Crijns HJGM, Van Gelder IC, Tieleman RG, et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997; 77: 56-61
39. Kirkorian G, Moncada E, Chevalier P, et al. Radiofrequency ablation of atrial flutter: efficacy of an anatomically guided approach. Circulation 1994; 90: 2804-14
40. Philippon F, Plumb VJ, Epstein AE, et al. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. Circulation 1995; 92: 430-5
41. Poty H, Suoudi N, Aziz AA, et al. Radiofrequency catheter ablation of type I atrial flutter: prediction of late success by electrophysiological criteria. Circulation 1995; 92: 1389-92
42. Fischer B, Haissaguerre M, Garrigues S, et al. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25: 1365-72
43. Cosio FG, Arribas F, Lopez-Gil M, et al. Radiofrequency ablation of atrial flutter. J Cardiovasc Electrophysiol 1996; 7: 60-70
44. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995: 108 (4 Suppl.): 352S-9S
45. Pentinga ML, Meeder JG, Crijns HJGM, et al. Late onset atrioventricular nodal tachycardia. Int J Cardiol 1993; 38: 293-8
46. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias: results and mochanisms. Circulation 1994; 89: 1074-89
47. Aronow WS, Epstein S, Koenigsberg M, et al. Usefulness of echocardiographic abnormal left ventricular ejection fraction. paroxysmal ventricular tachycardia, and complex ventricular arrhythmias in predicting new coronary events in patients over 62 years of age. Am J Curdiol 1988; 61: 1349-51
48. Aronow WS, Epstein S. Usefulness of silent ischemia, ventricular tachycardia, and complex ventricular arrhythmias in predicting new coronary events in elderly patients with coronary artery disease or systemic hypertension. Am J Cardiol 1990; 65: 511-2
49. Aronow WS, Epstein S, Koenigsberg M, et al. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988; 62: 1124-5
50. Buxton AE, Marchlinsky FE, Waxman HL, et al. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984; 53: 1275-9
51. Wiesfeld ACP, Crijns HJGM, Tuininga YS, et al. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation, Pacing Clin Electrophysiol 1996; 19: 1026-35
52. Brodsky MA, Orlov MV, Allen BJ, et al. Clinical assessment of adrenergic lone and responsiveness to beta-blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease. Am Heart J 1996; 131: 51-8
53. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients: the Beta-Blocker Heart Attack Trial experience. Circulation 1983; 67 Suppl. 1: 194-7
54. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients aged 65-75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179-84
55. Aronow WS, Ahn C, Mercando AD, et al. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994; 74: 819-21
56. The ESVEM Investigators. Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiology Study Versus Electrocardiographic Monitoring trial. Circulation 1993; 87: 323-9
57. Pfisterer M, Kiowski W, Burckhardt D, et al. Beneficial effects of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399-402
58. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991; 84: 550-7
59. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8
60. Singh SN, Fletcher RD, Gross Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82
61. Stevenson WG, Khan H, Sager P, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993; 88: 1647-70
62. Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994; 23: 1333-41
63. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40
64. Block M, Hammel D, Böcker D, et al. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? Am J Cardiol 1996; 78 Suppl. 5A: 62-8
65. Kim SG. Values and limitations of programmed stimulation and ambulatory monitoring in the management of ventricular tachycardia. Am J Cardiol 1988; 62: 71-121